N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N-1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.
1. A method for treating a neoplastic disease in a human or an animal, the method comprising administering to the human or the animal an effective amount of a compound represented by Formula (II):
or a pharmaceutically acceptable salt thereof,
wherein:
n is an integer of 0 or 1;
R is selected from the group consisting of halogen, hydroxy, a C 1-7 alkyl, a C 1-7 alkoxy, and —C(O)—O—C 1-5 alkyl;
R 1 is a linear or branched C 1-4 alkyl;
R 2 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, n-butyl, —CH 2 OCH 3 , —CH 2 OCH 2 CH 3 , and —CH 2 CH 2 OCH 3 ; and
Z is a bond, —CH 2 —, —CH 2 CH 2 —, —CH 2 OCH 2 —, —CH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 CH 2 —, or —C═C—.
2. The method of claim 1 , the neoplastic disease selected from bladder cancer, cervical dysplasia, cervical cancer, actinic keratosis, basal cell carcinoma, genital warts, herpes virus infection, cutaneous T-cell lymphoma, mycosis fungoides, Sezary Syndrome, HPV-positive oropharyngeal squamous cell carcinoma, Kaposi's sarcoma, melanoma, squamous cell carcinoma, renal cell carcinoma, acute myeloid leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B-cell lymphoma, hairy cell leukemia, and esophageal cancer.
3. The method of claim 1 , wherein the neoplastic disease is a neoplastic disease of the bladder or cervix.
4. The method of claim 1 , the compound of Formula (II) selected from the group consisting of:
1-[(1R)-1-(4-aminoimidazo[4,5-c]quinolin-1-yl)ethyl]cyclopentanol,
1-[(1R)-1-(4-aminoimidazo[4,5-c]quinolin-1-yl) propyl]cyclopentanol,
1-[(1R)-1-(4-aminoimidazo[4,5-c]quinolin-1-yl)ethyl]cyclopent-3-en-ol, and
1-[(1R)-1-(4-aminoimidazo[4,5-c]quinolin-1-yl) propyl]cyclohexanol.
5. A method for treating a T H 2-mediated disease in a human or animal, the method comprising administering to the human or animal an effective amount of a compound represented by Formula (II):
or a pharmaceutically acceptable salt thereof,
wherein:
n is an integer of 0 or 1;
R is selected the group consisting of halogen, hydroxy, a C 1-7 alkyl, a C 1 -7alkoxy, and —C(O)—O—C 1-5 alkyl;
R 1 is a linear or branched C 1-4 alkyl;
R 2 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, n-butyl,
—CH 2 OCH 3 , —CH 2 OCH 2 CH 3 , and —CH 2 CH 2 OCH 3 ; and
Z is a bond, —CH 2 —, —CH 2 CH 2 —, —CH 2 OCH 2 —, —CH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 CH 2 —, or —C═C—.
6. The method of claim 5 , the T H 2-mediated disease selected from atopic dermatitis, eczema, eosinophilia, asthma, allergy, allergic rhinitis, and Omenn's syndrome.
7. The method of claim 5 , the compound of Formula (II) selected from the group consisting of:
1-[(1R)-1-(4-aminoimidazo[4,5-c]quinolin-1-yl)ethyl]cyclopentanol,
1-[(1R)-1-(4-aminoimidazo[4,5-c]quinolin-1-yl) propyl]cyclopentanol,
1-[(1R)-1-(4-aminoimidazo[4,5-c]quinolin-1-yl)ethyl]cyclopent-3-en-ol, and
1-[(1R)-1-(4-aminoimidazo[4,5-c]quinolin-1-yl) propyl]cyclohexanol.
8. A pharmaceutical composition comprising:
1-[(1R)-1-(4-aminoimidazo[4,5-c]quinolin-1-yl)ethyl]cyclopentanol,
1-[(1R)-1-(4-aminoimidazo[4,5-c]quinolin-1-yl) propyl]cyclopentanol,
1-[(1R)-1-(4-aminoimidazo[4,5-c]quinolin-1-yl)ethyl]cyclopent-3-en-ol, or
1-[(1R)-1-(4-aminoimidazo[4,5-c]quinolin-1-yl) propyl]cyclohexanol; and
a pharmaceutically acceptable carrier.
9. The pharmaceutical composition of claim 8 , in the form of a topical gel, cream, or ointment.
10. A method of inducing cytokine biosynthesis in a human or an animal, the method comprising:
administering to the human or the animal an effective amount of a pharmaceutical composition of claim 8 .
11. A method of treating a neoplastic disease in a human or an animal, the method comprising:
administering to the human or the animal an effective amount of a pharmaceutical composition of claim 8 .
12. A method of treating a neoplastic disease in a human or an animal, the method comprising:
administering to the human or the animal an effective amount of a pharmaceutical composition of claim 9 .
13. The method of claim 12 , the neoplastic disease selected from bladder cancer, cervical dysplasia, cervical cancer, actinic keratosis, basal cell carcinoma, genital warts, herpes virus infection, cutaneous T-cell lymphoma, mycosis fungoides, Sezary Syndrome, HPV-positive oropharyngeal squamous cell carcinoma, Kaposi's sarcoma, melanoma, squamous cell carcinoma, renal cell carcinoma, acute myeloid leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B-cell lymphoma, hairy cell leukemia, and esophageal cancer.
14. The method of claim 12 , wherein the neoplastic disease is a neoplastic disease of the bladder or cervix.
15. A method of treating a T H 2-mediated disease in a human or an animal, the method comprising:
administering to the human or the animal an effective amount of a pharmaceutical composition of claim 8 .
16. A method of treating a T H 2-mediated disease in a human or an animal, the method comprising:
administering to the human or the animal an effective amount of a pharmaceutical composition of claim 9 .
17. The method of claim 16 , the T H 2-mediated disease selected from atopic dermatitis, eczema, eosinophilia, asthma, allergy, allergic rhinitis, and Omenn's syndrome.